Akhila Wimalasingham

426 total citations
10 papers, 210 citations indexed

About

Akhila Wimalasingham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Akhila Wimalasingham has authored 10 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Akhila Wimalasingham's work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (3 papers). Akhila Wimalasingham is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (3 papers). Akhila Wimalasingham collaborates with scholars based in United Kingdom, Germany and United States. Akhila Wimalasingham's co-authors include Bernadett Szabados, Thomas Powles, Thomas Powles, Simon Chowdhury, Yen Zhi Tang, Alfonso Gómez de Liaño, Christy Ralph, Matthew Wheater, Imtiaz Ahmed and Andrew Stockdale and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Akhila Wimalasingham

9 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akhila Wimalasingham United Kingdom 6 110 90 81 70 42 10 210
Isabela W. Cunha Brazil 8 159 1.4× 58 0.6× 57 0.7× 101 1.4× 92 2.2× 14 301
László Agócs Hungary 5 104 0.9× 96 1.1× 220 2.7× 63 0.9× 37 0.9× 20 290
Ian Y. Luk Australia 9 134 1.2× 29 0.3× 61 0.8× 35 0.5× 48 1.1× 11 214
N. А. Oskina Russia 6 89 0.8× 249 2.8× 201 2.5× 34 0.5× 31 0.7× 15 339
Ina Valeria Zurlo Italy 6 36 0.3× 89 1.0× 105 1.3× 42 0.6× 40 1.0× 24 191
Christoforos Astaras Switzerland 6 68 0.6× 69 0.8× 129 1.6× 41 0.6× 49 1.2× 11 207
Grégoire Marret France 8 96 0.9× 74 0.8× 119 1.5× 27 0.4× 48 1.1× 24 231
Hiroshi Imazeki Japan 10 54 0.5× 143 1.6× 206 2.5× 74 1.1× 24 0.6× 31 308
G. Hommel Germany 7 194 1.8× 108 1.2× 118 1.5× 106 1.5× 40 1.0× 8 349
Deyun Luo China 7 113 1.0× 52 0.6× 76 0.9× 42 0.6× 38 0.9× 22 206

Countries citing papers authored by Akhila Wimalasingham

Since Specialization
Citations

This map shows the geographic impact of Akhila Wimalasingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akhila Wimalasingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akhila Wimalasingham more than expected).

Fields of papers citing papers by Akhila Wimalasingham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akhila Wimalasingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akhila Wimalasingham. The network helps show where Akhila Wimalasingham may publish in the future.

Co-authorship network of co-authors of Akhila Wimalasingham

This figure shows the co-authorship network connecting the top 25 collaborators of Akhila Wimalasingham. A scholar is included among the top collaborators of Akhila Wimalasingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akhila Wimalasingham. Akhila Wimalasingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Szlosarek, Peter W., Akhila Wimalasingham, Melissa Phillips, et al.. (2021). Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer Medicine. 10(19). 6642–6652. 14 indexed citations
2.
3.
Winer, Ira, Akhila Wimalasingham, Joaquina Baranda, et al.. (2021). 531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts. SHILAP Revista de lepidopterología. A562–A562. 1 indexed citations
4.
5.
Szabados, Bernadett, Nick van Dijk, Yen Zhi Tang, et al.. (2017). Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology. 73(2). 149–152. 70 indexed citations
6.
Ackerman, Charlotte, Sanjeev Mariathasan, Dorothee Nickles, et al.. (2017). Molecular subtyping of metastatic urothelial bladder cancer.. Journal of Clinical Oncology. 35(6_suppl). 326–326.
7.
Szabados, Bernadett, Akhila Wimalasingham, Yen Zhi Tang, et al.. (2017). High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy.. Journal of Clinical Oncology. 35(6_suppl). 377–377. 2 indexed citations
8.
Rose, Tracy L., Allison M. Deal, Sylvain Ladoire, et al.. (2016). Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2(4). 405–413. 12 indexed citations
9.
Powles, Thomas, Syed A. Hussain, Andrew Protheroe, et al.. (2016). PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. Journal of Clinical Oncology. 34(2_suppl). 430–430. 5 indexed citations
10.
Powles, Thomas, Matthew Wheater, Omar Din, et al.. (2015). A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology. 69(3). 450–456. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabela W. Cunha Breakdown of academic impact, for papers by László Agócs Breakdown of academic impact, for papers by Ian Y. Luk Breakdown of academic impact, for papers by N. А. Oskina Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Christoforos Astaras Breakdown of academic impact, for papers by Grégoire Marret Breakdown of academic impact, for papers by Hiroshi Imazeki Breakdown of academic impact, for papers by G. Hommel Breakdown of academic impact, for papers by Deyun Luo
Rankless by CCL
2026